Antineoplastics
1
Reactions 470 - 25 Sep 1993 Antineoplastics Lack of adverse effects on pulmonary function: clinical study A long-term controlled follow-up study of 94 evaluable patients with testicular cancer concludes that 3-4 courses of combination antineoplastic therapy with bleomycin, cisplatin and etoposide/vinblastine does not lead to long-term impairment of pulmonary function, provided that the cumulative dose of bleomycin does not exceed 300mg. 25 patients received 3 cycles of post-operative antineoplastic therapy with cisplatin and bleomycin in combination with vinblastine or etoposide, and 22 patients received 4 cycles. The average cumulative dose of bleomycin was 277.7mg and of cisplatin 645.4mg. The remaining 47 patients did not receive antineoplastics. Pulmonary function was assessed 6-12 years later by spirometry and the single breath holding method for diffusion capacity. The study revealed only 8.2% of clinically silent changes on chest x-rays, during treatment with bleomycin. Author comment: ‘The pulmonary function seemed to be more influenced by smoking than by previous chemotherapy.’ Lehne G, et al. Long-term follow-up of pulmonary function in patients cured from testicular cancer with combination chemotherapy including bleomycin. British Journal of Cancer 68: 555-558, Sep 1993 - Norway 800220007 1 Reactions 25 Sep 1993 No. 470 0114-9954/10/0470-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 470 - 25 Sep 1993
Antineoplastics
Lack of adverse effects on pulmonary function:clinical study
A long-term controlled follow-up study of 94 evaluablepatients with testicular cancer concludes that 3-4 courses ofcombination antineoplastic therapy with bleomycin, cisplatinand etoposide/vinblastine does not lead to long-termimpairment of pulmonary function, provided that thecumulative dose of bleomycin does not exceed 300mg.
25 patients received 3 cycles of post-operativeantineoplastic therapy with cisplatin and bleomycin incombination with vinblastine or etoposide, and 22 patientsreceived 4 cycles. The average cumulative dose of bleomycinwas 277.7mg and of cisplatin 645.4mg. The remaining 47patients did not receive antineoplastics.
Pulmonary function was assessed 6-12 years later byspirometry and the single breath holding method for diffusioncapacity. The study revealed only 8.2% of clinically silentchanges on chest x-rays, during treatment with bleomycin.
Author comment: ‘The pulmonary function seemed to bemore influenced by smoking than by previous chemotherapy.’Lehne G, et al. Long-term follow-up of pulmonary function in patients cured fromtesticular cancer with combination chemotherapy including bleomycin. BritishJournal of Cancer 68: 555-558, Sep 1993 - Norway 800220007
1
Reactions 25 Sep 1993 No. 4700114-9954/10/0470-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
